Raymond James & Associates Acquires 4,660 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Raymond James & Associates lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,348 shares of the medical research company’s stock after purchasing an additional 4,660 shares during the period. Raymond James & Associates owned 0.48% of Charles River Laboratories International worth $67,290,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. abrdn plc grew its position in shares of Charles River Laboratories International by 872.0% during the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock worth $28,795,000 after buying an additional 109,275 shares during the period. Regency Capital Management Inc. DE bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $3,703,000. WCM Investment Management LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $1,396,000. DekaBank Deutsche Girozentrale lifted its holdings in shares of Charles River Laboratories International by 98.6% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after purchasing an additional 6,997 shares in the last quarter. Finally, AMG National Trust Bank acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at $1,119,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL traded up $3.58 during trading hours on Friday, reaching $233.47. 466,193 shares of the company were exchanged, compared to its average volume of 482,082. The stock has a market capitalization of $12.03 billion, a P/E ratio of 25.35, a P/E/G ratio of 1.80 and a beta of 1.44. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The business’s 50 day simple moving average is $252.23 and its 200-day simple moving average is $223.97.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same quarter last year, the business posted $2.98 EPS. Charles River Laboratories International’s quarterly revenue was down 7.9% compared to the same quarter last year. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Analysts Set New Price Targets

CRL has been the topic of a number of recent research reports. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Citigroup boosted their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. UBS Group increased their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.23.

Insider Transactions at Charles River Laboratories International

In related news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at approximately $3,437,635. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).